Drug Costs

Criticism of prescription drug middlemen has intensified recently in the wake of a federal agency’s actions and legislative reform attempts.

President Joe Biden is campaigning on his efforts to cut drug costs for Medicare patients. But independent pharmacists say one strategy makes it unaffordable for them to keep some brand-name medicines in stock.

Independent pharmacists say they're losing money on many prescriptions they fill. “It’s just a lot of different elements in the system all at once," says a pharmacy assistant professor at FAMU.

The FDA said Florida’s program will be authorized for two years, and state officials must test the drugs to make sure they’re authentic and relabel them so that they comply with U.S. standards.

Colorado officials say they haven’t been able to stand up a program to import drugs from Canada because of drugmaker opposition — and the Biden administration’s inaction.

The governors square off in a first-of-its-kind debate Thursday. Let's compare the political rivals’ health care positions, showing how their policies helped — or hinder— the health of their states’ residents.

Monica Bertagnolli appeared before a Senate committee this past week. Her confirmation has been held up by Sen. Bernie Sanders, who has demanded the president work more aggressively to lower prescription prices.

This week on The Florida Roundup, we discuss how, for the first time, Medicare will negotiate the prices of 10 common medicines. Plus, we look at the latest in education news and hear about how a Florida woman and her granddaughter made history – six decades apart.

The Biden administration unveiled the first 10 drugs subject to price negotiations, taking a swipe at the pharmaceutical industry. But what does it mean for patients?

With a decision expected this fall on whether Florida can import cost-saving drugs, the state lashed out after federal officials raised issues such as a requirement for a secured warehouse in Michigan.

Brand-name drug prices in the U.S. — more than three times the price in other developed countries — are related neither to the amount of research and development nor their therapeutic value, research shows.

The state alleges the federal agency violated the Freedom of Information Act. The revised lawsuit includes allegations that the FDA did not properly respond to a records request submitted in May.